Subscribe to Search results

Approval was sought for planning to proceed on the assumption that BPL would process all the plasma for both England and Wales as the PFC did not have additional capacity without introducing three shift patterns.

Published on:

The Treasury approved the redevelopment in principle and agreed that the project should be fast-tracked.

Published on:

In a report, Dr Lane outlined that the final cost of MARP01 would be £2.8 million.

Published on:

Construction of BPL finally began in May 1983. The original completion date was to be July 1985.

Published on:

In a written answer on the NBTS and Factor 8, Kenneth Clarke, the Minister of State for Health, stated that "We decided in 1982 that this country should become self-sufficient in blood products".

Published on:

Lord Owen's reaction to Kenneth Clarke's words on self-sufficiency, in his written statement to the Inquiry, was that it was "extremely odd" and "as if the previous Labour Government programme had never existed".

Published on:

Lord Fowler noted in his evidence to the Inquiry that ministers invested money at a very considerable level, especially given the financial pressures on health spending. It was given priority at the expense of other pressing matters.

Published on:

Considering the evidence, there was always likely to be sufficient cryoprecipitate capable of being produced. However, clinicians, and no doubt many patients too, wished for the added advantages which factor concentrates offered, particularly in terms of home therapy.

Published on:

In wartime planning, two main plants were to process plasma for the UK: one south, one north.

Published on:

Dr Cumming was an enthusiastic advocate of forward planning when it came to plasma production.

Published on:

The Ministry of Health agreed with the SHHD that the PFC would fractionate plasma for the NHS using plasma collected by the Newcastle, Leeds, Manchester and Liverpool regions.

Published on:

The Blood Transfusion Public Expenditure Survey Committee issued a report regarding a statement on forecast assessments.

Published on:

The Scottish Home and Health Department suggested that there should be a management policy committee covering both the Blood Products Laboratory and the Protein Fractionation Centre to ensure that a common production policy would apply to both laboratories.

Published on:

It was not until 1965 that planning for a 1972 extension to the Blood Products Laboratory, which then followed, contemplated accommodating the fractionation of plasma on any scale. This was a necessary step in producing clotting factor concentrates, though the main reason for the expansion at the time was to produce more immunoglobulin to prevent rubella in pregnancy, following an outbreak.

Published on:

Pressure on the Government to act on increasing the supply of plasma was exerted by clinicians, by the medical press, by NBTS, and by the advisory bodies which had been set up.

Published on:

The setting up of a Joint Steering Committee on Blood Products Production was precipitated by the grant of product licences to two commercial firms "which might entail large sums being spent by NHS authorities on these products."

Published on:

The Scottish CMO, Sir John Brotherson, wrote from Scotland offering further support for blood product production capabilities south of the border.

Published on:

It had been decided that 1,000 litres of fresh or fresh frozen plasma could be processed weekly by PFC, using pools of eight litres. This size of pool could be handled conveniently and quickly and was supported by clinicians using the material.

Published on:

It was considered that, as there was only a small possibility of expansion at Elstree, Edinburgh should be prepared to cope with the requirements of a larger part of England than originally intended so that the total growth of requirement could be handled by the two Blood Products Units. Dr Maycock considered that this approach to long-term planning was the only correct procedure.

Published on:

The DHSS invested £400,000 in the Protein Fractionation Centre towards the capital costs.

Published on: